Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 47

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 47
---

and we continue to enjoy freedom to use panobinostat for research purposes and we plan to continue to pursue development of MTX110. We
believe that the relevant Secura Bio patents may delay a launch of MTX110 for use in patients with DMG should the product receive accelerated
approval, however we do not anticipate it would have any impact on launching MTX110 for use in patients with GBM. If we are unable to
launch a product candidate until the patent expires, there could be a material adverse effect on our business, financial condition and
results of operations.

Commercial Agreements, Strategic Partnerships and Collaborations

We are currently collaborating
with biopharmaceutical companies, contract research organizations and universities on several of our development programs.

Emtora License Agreement.
On April 25, 2024, we entered into a license and collaboration agreement, or the Emtora License Agreement, with Emtora, relating to the
license of eRapa, an oral product formulation of rapamycin (sirolimus), or the Product, for use in the prevention, treatment, diagnosis,
detection, monitoring and/or predisposition testing of all diseases, states or conditions in humans, or the Field, that includes the nanoparticle
and enteric coated finished pharmaceutical formulations developed at any time by Emtora and its affiliates, or the License. Under the
License, we obtained from Emtora an exclusive, worldwide, sublicensable right to develop, manufacture, commercialize, or otherwise exploit
products containing rapamycin (sirolimus) in the Field. Pursuant to the terms of the License Agreement, the Company and Emtora established
a joint development committee, consisting of two designees of the Company and two designees of Emtora.

As consideration for the License,
we made an upfront payment to Emtora in the form of 1,512 of our Depositary Shares (equal to five percent (5%) of our outstanding Ordinary
Shares, calculated on a fully-diluted basis (including in-the-money warrants) at the time). In addition, we are also responsible for up
to $31.5 million in sales milestones within the first six months of commercial sale of a first-approved indication of eRapa in certain
markets, with decreasing milestones for subsequent approvals for additional indications. There is also a one-time $10.0 million milestone
payable upon cumulative net sales of $1.0 billion. Further, we are also